Search clinical trials for: Tiotropium & olodaterol

Total 436 results

Boehringer Ingelheim

Completed

Efficacy and Safety of Ba679BR Powder Inhalation in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Comparative Pharmacokinetics and Pharmacodynamics of Tiotropium With Ipratropium or Placebo After 19 Days of Tiotropium Treatment

Healthy
Xiromed LLC
Laboratorios Liconsa; Exeltis

Completed

Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD) (ARBORUS)

COPD

United States, India
Boehringer Ingelheim

Completed

Efficacy and Safety of Free Combination of Tiotropium + Formoterol Compared to Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Belgium, France, Germany, Italy, Netherlands, New Zealand, Portugal, Russian Federation, United Kingdom
Novartis Pharmaceuticals

Completed

A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD) (INTENSITY)

Chronic Obstructive Pulmonary Disease

United States, Spain, Switzerland, France, Italy, Germany, Turkey, Hungary, Norway, Slovakia, Poland, Russian Federation, Canada, Belgium, Austria, Colombia, Denmark, Finland, Greece, Israel, Mexico, United Kingdom
Amgen

Completed

Juvenile Rheumatoid Arthritis

Juvenile Chronic Arthritis
Novartis Pharmaceuticals

Completed

Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD

COPD

Germany, Spain, United Kingdom, Italy
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study Comparing Tiotropium Easyhaler® and Spiriva® HandiHaler® (TESSA)

Healthy Volunteers

Finland
Boehringer Ingelheim

Completed

Tiotropium in Combination With Concomitant Cimetidine or Ranitidine in Healthy Male and Female Subjects

Healthy
Virginia Commonwealth University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Interleukin-1 Blockade in HF With Preserved EF (D-HART2)

Heart Failure With Normal Ejection Fraction

United States
The Korean Academy of Tuberculosis and Respiratory...
GlaxoSmithKline

Completed

Clinical Outcomes of Tiotropium Plus Fluticasone Propionate/Salmeterol Compared With Tiotropium for Chronic Obstructive Pulmonary Disease (COPD) in Korea

Chronic Obstructive Pulmonary Disease

Korea, Republic of
University of Utah

Completed

Interleukin-1 Receptor Antagonist for the Treatment of Heart Failure in Patients With Left Ventricular Assist Devices

Heart Failure

United States
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Terminated

Bronchodilators and Respiratory Mechanics in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

Italy
Federal University of São Paulo

Completed

Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients

Pulmonary Disease, Chronic Obstructive | Pulmonary Emphysema | Chronic Bronchitis

Brazil
Boehringer Ingelheim

Completed

Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma

Asthma

United States, Canada, France, Germany
Boehringer Ingelheim

Completed

Tiotropium and Salmeterol PK Study in COPD Patients

Pulmonary Disease, Chronic Obstructive

Belgium, Netherlands
Boehringer Ingelheim
Pfizer

Completed

Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.

Pulmonary Disease, Chronic Obstructive

Austria, Belgium, Bulgaria, Czech Republic, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slovakia, Slovenia, Spain, Turkey, Ukraine, United...
Boehringer Ingelheim

Completed

Safety and Effectiveness of Spiriva in COPD (Chronic Obstructive Pulmonary Disease) Patients Under the Real Condition of Usual Practice

Pulmonary Disease, Chronic Obstructive

Taiwan
Royal Free and University College Medical School
Boehringer Ingelheim

Completed

Effect of Tiotropium on Inflammation and Exacerbations in COPD

Chronic Obstructive Pulmonary Disease

United Kingdom
Diabetes Care Center

Completed

A Comparison of Two Initial Dosing Formulas

Diabetes Mellitus, Type 2

United States
Elpen Pharmaceutical Co. Inc.

Not yet recruiting

QualiTy of Life Evaluation in Patients With ChRonic ObstructIve Pulmonary Disease Who Require Tiotropium as additiOnal treatmeNt. (TRITON)

COPD
GlaxoSmithKline

Completed

GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany, United States
GlaxoSmithKline

Completed

A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD) (AC4115321)

Pulmonary Disease, Chronic Obstructive

United States
3M

Completed

Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With Reference

Healthy
Boehringer Ingelheim

Completed

A Collection of Vital Status and Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely From Tiotropium Inhalation Solution Delivered by the Respimat Inhaler

Pulmonary Disease, Chronic Obstructive

Australia, New Zealand, United Kingdom
Boehringer Ingelheim

Completed

Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection

Pulmonary Disease, Chronic Obstructive

United States
AstraZeneca

Terminated

A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease | COPD

Poland, Sweden
Boehringer Ingelheim

Completed

Comparison of Tiotropium and Ipratropium in a Double-Blind, Double-dummy, Efficacy and Safety Study in Adults With COPD

Pulmonary Disease, Chronic Obstructive

Korea, Republic of
Novartis

Completed

A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control

Chronic Obstructive Pulmonary Disease (COPD)

Spain, Germany, South Africa, Australia, Poland, New Zealand, Netherlands
Boehringer Ingelheim

Completed

Efficacy and Safety (Including 24-hour Holter Monitoring) of Tiotropium Inhalation Capsules in Patients With COPD

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Measure of the Long Term Influence of SPIRIVA® in Acute Respiratory Disorders

Pulmonary Disease, Chronic Obstructive

France
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

COPD

Germany
Novo Nordisk A/S

Completed

Observational Study to Evaluate Safety of Levemir® in Type 1 and Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Indonesia
Neutec Ar-Ge San ve Tic A.Ş

Completed

Comparison of 24 Hour Bronchodilator Efficacy of Tiotropium 18 mcg Delivered Via DISCAIR Versus SPIRIVA 18 µg Delivered Via HANDIHALER® in Patients With Moderate to Severe COPD

COPD
Orion Corporation, Orion Pharma

Completed

Effect of Charcoal on Gastrointestinal Absorption of Tiotropium (TIOBLOCK)

Healthy Volunteer Study

Finland
Hamilton Health Sciences Corporation

Unknown

Study of a Tiotropium Inhaler For Shortness of Breath in Advanced Non-Small Cell Lung Cancer (TIDAL)

NSCLC | Dyspnea

Canada
Boehringer Ingelheim

Completed

Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Australia, Austria, Belgium, Brazil, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Ireland, Italy, Japan, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Philip... and more
Boehringer Ingelheim

Completed

Tiotropium / Respimat One Year Study in COPD.

Pulmonary Disease, Chronic Obstructive

United States, Australia, Brazil, Canada, China, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Italy, Korea, Republic of, Lithuania, Malaysia, Mexico, Netherlands, Norway, Portugal, Singapore, Slovakia, South... and more
Boehringer Ingelheim

Completed

Pharmacokinetics of the Fixed Dose Combination of Tiotropium Plus BI 54903 Versus the Combination of the Monoproducts of Tiotropium and BI 54903 in Healthy Volunteers

Healthy

Germany
NHS Greater Glasgow and Clyde

Withdrawn

Replacement of Nebulised Ipratropium With Inhaled Tiotropium in Stable Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United Kingdom
Boehringer Ingelheim

Completed

Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

Pulmonary Disease, Chronic Obstructive

Germany, Italy, Switzerland, South Africa
Boehringer Ingelheim

Completed

Multiple Rising Inhalative Doses of BI 1744 CL in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Effect of Spiriva on the Activities of Daily Living Score Recommended in Austrian COPD Guidelines

Pulmonary Disease, Chronic Obstructive

Austria
Boehringer Ingelheim

Completed

A Prescription-Event Monitoring (PEM) Study of Tiotropium

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Effects of a 9-months Treatment of SPIRIVA on Health Related Quality of Life in Patients With COPD

Pulmonary Disease, Chronic Obstructive

France
Boehringer Ingelheim

Completed

Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States

3

Subscribe